Company: GANX
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001558370-25-004958
Chunk: 40

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 40
---
. Equity-Based Incentive Awards Our equity-based incentive awards granted to our named executive officers are designed to align our interests and those of our stockholders with those of our employees and consultants, including our executive officers. Historically, we have used stock options as an incentive for long-term compensation to our executive officers because the options allow our executive officers to profit from this form of equity compensation only if our stock price increases relative to the option’s exercise price, which exercise price is set at the fair market value of our shares of common stock on the date of grant. We have also used restricted stock unit awards as long-term incentives for our executive officers, in combination with or without stock option awards. Vesting of equity awards is generally tied to each officer’s continuous service with us and serves as an additional retention measure. We may grant equity awards at such times as our Board or Compensation Committee determines appropriate. Our executives generally are awarded an initial grant in the form of an option, at times accompanied by restricted stock units, in connection with their commencement of employment with us. Additional grants may occur periodically in order to specifically incentivize executives with respect to achieving certain corporate goals or to reward executives for exceptional performance.

All options are granted with an exercise price per share that is no less than the fair market value of our common stock on the date of grant of such award. Our option awards generally vest over a four-year period and may be subject to acceleration of vesting and exercisability under certain termination and change in control events. See “—Outstanding Equity Awards at Fiscal Year End” for further information regarding option and stock awards granted during fiscal 2024.

Outstanding Equity Awards at Fiscal Year End The following table sets forth certain information regarding outstanding equity awards granted to our named executive officers that remained outstanding as of December 31, 2024.

| ​                              | ​ | ​             | ​ |           ​ | ​    |             ​ | ​    |        ​ | ​ | ​          | ​    | ​            | ​    | ​          |
| ​                              |   | Option Awards |   |             |      |               |      |          |   |            |      | Stock Awards |      |            |
| ​                              | ​ | ​             | ​ |           ​ | ​    |             ​ | ​    |        ​ | ​ | ​          | ​    | ​            | ​    | Market     |
| ​                              | ​ | ​             | ​ |           ​ | ​    |             ​ | ​    |